D.A. Davidson & Co’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.8M Buy
77,509
+10,586
+16% +$1.48M 0.07% 232
2025
Q4
$8.21M Buy
66,923
+5,159
+8% +$627K 0.05% 274
2025
Q3
$6.86M Sell
61,764
-663
-1% -$75.4K 0.04% 294
2025
Q2
$6.92M Sell
62,427
-8,638
-12% -$919K 0.05% 270
2025
Q1
$7.96M Sell
71,065
-11,159
-14% -$1.15M 0.06% 230
2024
Q4
$7.6M Sell
82,224
-293
-0.4% -$26.4K 0.06% 227
2024
Q3
$6.92M Sell
82,517
-22,070
-21% -$1.68M 0.06% 244
2024
Q2
$7.18M Sell
104,587
-16,074
-13% -$1.07M 0.06% 223
2024
Q1
$8.84M Buy
120,661
+23,567
+24% +$1.81M 0.08% 197
2023
Q4
$7.87M Buy
97,094
+917
+1% +$71.4K 0.08% 203
2023
Q3
$7.21M Buy
96,177
+2,609
+3% +$201K 0.08% 200
2023
Q2
$7.21M Buy
93,568
+3,954
+4% +$315K 0.08% 207
2023
Q1
$7.43M Sell
89,614
-5,767
-6% -$478K 0.08% 200
2022
Q4
$8.19M Sell
95,381
-8,664
-8% -$686K 0.1% 175
2022
Q3
$6.42M Buy
104,045
+14,816
+17% +$934K 0.08% 191
2022
Q2
$5.51M Buy
89,229
+1,791
+2% +$111K 0.07% 223
2022
Q1
$5.2M Buy
87,438
+5,319
+6% +$340K 0.06% 256
2021
Q4
$5.97M Buy
82,119
+3,701
+5% +$255K 0.06% 239
2021
Q3
$5.48M Buy
78,418
+5,936
+8% +$417K 0.06% 238
2021
Q2
$4.99M Buy
72,482
+2,241
+3% +$150K 0.06% 254
2021
Q1
$4.54M Sell
70,241
-1,545
-2% -$99.6K 0.06% 251
2020
Q4
$4.17M Buy
71,786
+8,896
+14% +$537K 0.06% 214
2020
Q3
$3.97M Sell
62,890
-7,415
-11% -$514K 0.07% 201
2020
Q2
$5.41M Sell
70,305
-52,487
-43% -$4.02M 0.1% 145
2020
Q1
$9.19M Buy
122,792
+54,955
+81% +$3.8M 0.18% 97
2019
Q4
$4.41M Buy
67,837
+3,385
+5% +$220K 0.07% 211
2019
Q3
$4.08M Sell
64,452
-8,403
-12% -$549K 0.07% 212
2019
Q2
$4.92M Sell
72,855
-4,618
-6% -$304K 0.09% 169
2019
Q1
$5.03M Sell
77,473
-6,171
-7% -$410K 0.09% 178
2018
Q4
$5.23M Sell
83,644
-448
-0.5% -$31.3K 0.1% 164
2018
Q3
$6.49M Sell
84,092
-3,377
-4% -$255K 0.12% 148
2018
Q2
$6.2M Buy
87,469
+3,863
+5% +$273K 0.12% 146
2018
Q1
$6.3M Buy
83,606
+6,757
+9% +$537K 0.13% 134
2017
Q4
$5.5M Sell
76,849
-16,883
-18% -$1.28M 0.12% 148
2017
Q3
$7.59M Buy
93,732
+1,317
+1% +$101K 0.15% 144
2017
Q2
$6.54M Buy
92,415
+2,685
+3% +$179K 0.15% 128
2017
Q1
$6.09M Sell
89,730
-114,450
-56% -$8.05M 0.15% 123
2016
Q4
$14.6M Buy
204,180
+16,373
+9% +$1.22M 0.33% 62
2016
Q3
$14.9M Buy
187,807
+39,897
+27% +$3.24M 0.37% 60
2016
Q2
$12.3M Buy
147,910
+51,716
+54% +$4.59M 0.36% 61
2016
Q1
$8.83M Buy
96,194
+15,655
+19% +$1.41M 0.28% 75
2015
Q4
$8.14M Buy
80,539
+4,251
+6% +$442K 0.27% 79
2015
Q3
$7.49M Buy
76,288
+1,906
+3% +$212K 0.26% 73
2015
Q2
$8.7M Buy
74,382
+273
+0.4% +$29.8K 0.29% 71
2015
Q1
$7.27M Buy
74,109
+14,684
+25% +$1.49M 0.24% 85
2014
Q4
$5.6M Buy
59,425
+2,936
+5% +$304K 0.18% 112
2014
Q3
$6.01M Buy
56,489
+4,615
+9% +$452K 0.2% 97
2014
Q2
$4.29M Sell
51,874
-4,395
-8% -$342K 0.15% 137
2014
Q1
$3.98M Sell
56,269
-20,114
-26% -$1.58M 0.14% 141
2013
Q4
$5.73M Buy
76,383
+722
+1% +$50.3K 0.21% 93
2013
Q3
$4.75M Buy
75,661
+1,796
+2% +$107K 0.21% 100
2013
Q2
$3.78M Buy
+73,865
New +$3.85M 0.18% 114

Other funds holding GILD

D.A. Davidson & Co's GILD Position: Q1 2026 in Review

D.A. Davidson & Co increased its Gilead Sciences (GILD) stake by 16% in Q1 2026, buying an estimated $1.48M and bringing the position to 77,509 shares worth $10.8M. The position accounts for 0.07% of the portfolio, ranked #232.

D.A. Davidson & Co first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $14.9M in Q3 2016. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • D.A. Davidson & Co held 77,509 shares of Gilead Sciences worth $10.8M as of Q1 2026.
  • D.A. Davidson & Co bought 10,586 Gilead Sciences shares in Q1 2026, an estimated $1.48M.
  • Gilead Sciences made up 0.07% of D.A. Davidson & Co's portfolio in Q1 2026, its #232 holding.
  • D.A. Davidson & Co first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • D.A. Davidson & Co's Gilead Sciences position peaked at $14.9M in Q3 2016.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on D.A. Davidson & Co's 13F filing for Q1 2026, filed 5 May 2026.